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TXonclusions
his study demonstrates that lungs from older donors could
e considered for transplantation if they fulfill all other lung
onor selection criteria. An evaluation of the postoperative
isk should, however, be performed on the basis of donor
haracteristics and recipient diagnosis. Recipients with pul-
onary fibrosis or pulmonary hypertension certainly present
igher-risk recipients in whom older donors should be used
autiously. Although donor age can affect long-term sur-
ival posttransplantation, given the current shortage of or-
ans, older donors should be considered for lung transplan-
ation and not be discarded on the basis of age only.
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iscussion
r J. Wain (Boston, Massachusetts). I thank the Society for the
pportunity to discuss the article and congratulate Dr De Perrot
nd the Toronto group on an impressive experience and a timely
resentation for us about lung transplantation. The issue of a
imited supply of donors for lung transplantation is truly critical at
he present time, and the group here is certainly to be congratulated
or the courage to take donors in increasing numbers, both 60 and
0 years of age or older, as well as the forthright presentation of
he results in using these donors themselves. I think the general
onclusion of the study, that donors more than 60 years of age can
rovide acceptable organs for lung transplantation in selected
ircumstances, is sound and valid. The results of the study cer-
ainly underscore the paradigm that, short of active malignancy, no
ne single demographic or physiologic characteristic should rule
ut a potential lung donor candidate, and clearly age should be
hrown out based on this experience. I have 4 questions. First, the
ime course of the study, 1994 to 2005—did you use any older
onors before 1994? Was that the first year that you began using
hose donors?
Dr De Perrot. Yes, 1994 was the first year a donor older than
0 years was used in our experience.
Dr Wain. Great. That’s what I presumed was probably the
ase, because you can clearly see from the graph that you were
sing more and more of the donors over time.
Second, why do you think it is that the older donors don’t do as
ell in recipients with a diagnosis of pulmonary fibrosis or pul-
onary hypertension? Do you think there is intrinsic disease in
hose donor lungs that is not identified, or is there some other
actor?
Dr De Perrot. I think the older donors don’t have the same
otential to sustain postoperative complications as younger donors
o. One question that we are starting to look at is pulmonary
ypertension. We are trying to determine whether the patient with
ulmonary fibrosis who died with older lungs had high pulmonary
rtery pressures at the time of surgery or not, but I don’t have the
ata yet.
Dr Wain. Well, that would certainly make sense, and from that
erspective, are there any other studies one can do on these older
onors before procurement, such as a computed tomography scan
r angiographic imaging, that might help you to select them better?
Dr De Perrot. We haven’t done any of that. It’s always
otentially a problem to have underlying lung disease that you
on’t detect at the time of retrieval. The risk is higher in older
onors but can be encountered in younger donors too. What we
ave done in addition to our standard evaluation is more routinely
easure the pulmonary artery pressures in the donor. Certainly this
eries of donors, in addition to the age, have been very good
onors. So the older they get, the more strict we are with the
riteria other than age.
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De Perrot et al Cardiothoracic TransplantationDr Wain. I see. The last question, really to help guide the rest
f us if we’re not quite as brave as you are, is how would you
escribe the ideal recipient for a set of lungs from a donor aged
ore than 60 years, and perhaps more important, who would you
ay absolutely should never get a set of donor lungs from someone
ged more than 60 years?
Dr De Perrot. I would be very cautious about using older lungs
or patients with pulmonary hypertension, but it really comes down
o how sick the recipients are on the waiting list. These lungs have
een used for recipients who were very sick and would not have
urvived for long without a transplant.
Dr Wain. The recipient age, for instance, wouldn’t be some-
hing that you would look at critically?
Dr De Perrot. We would rather put old lungs into an old
ecipient, but if you have somebody who is young and very sick on
he waiting list, we would use these lungs as well.
Dr J. Sonett (New York, New York). So you would use a
2-year-old lung in a 20-year-old with cystic fibrosis even with the
uestionable increased BOS rate?
Dr De Perrot. Yes. If the recipient is clearly sick, for instance,
ith high CO2 or in the hospital on biphasic positive airway
ressure, we would use these lungs.
Dr Wain. I congratulate you on this study, and I want to hear
ore about it in a couple of years and see how things continue to
urn out.
Dr S. Keshavjee (Toronto, Ontario, Canada). I know Marc
entioned measuring pulmonary artery pressures, and if your
onor doesn’t have a Swan, one should at least check it with a
ressure line, because we have turned down some older donors in
hom we found significant pulmonary hypertension at the time of
rgan retrieval. Furthermore, it is important to note that when you
ook at our experience of the mortalities in those with idiopathic
ulmonary fibrosis and primary pulmonary hypertension with an
ld donor, it’s often that clinical situation in which you have a
ecipient who is desperately ill and you stick your neck out
hinking, well, this is going to be their last chance, and yes, it’s
isky, but they don’t really have another opportunity; however,
hen you look back at your data you inevitably see increased
ortality in the high-risk recipients, such as those with pulmonary
ypertension. So when Dr Wain asked the question of who abso-
utely shouldn’t get it, one needs to examine this in the context of
he fact that often when we do that, it’s in extenuating clinical
ircumstances, of compounding risks, using a high-risk donor for
high-risk recipient.
Dr Y. Toyoda (Pittsburgh, Pennsylvania). I have a similar
uestion. We performed 91 lung transplants last year. Of these,
bout 10% had donors aged 60 years or more. So we are very
The Journal of Thoracicomfortable with the donor age up to 65 years now, but beyond 65
ears, we try to use donors locally. We use older donors for older
ecipients. Is your conclusion that older donors provide a worse
utcome perhaps related to the older recipient population?
Dr De Perrot. Using older donors for older recipients can
rovide a worse outcome?
Dr Toyoda. Yes, worse survival.
Dr De Perrot. The recipient age doesn’t seem to be a factor
hat will lead to more complications. Recipients with pulmonary
brosis are usually older, but the recipient age in itself, in our
xperience at least, didn’t seem to make a difference in the
ecovery from the surgery.
Dr P. Theodore (San Francisco, California). Marc, thank you
or that lucid presentation. We have been impressed, and your data
eem similar in a lot of the ischemia-reperfusion injury that we see
n older donors, and I noticed in those patients who died, it looked
ike upward of 30% had primary graft dysfunction. I have often
ondered if the older donors are less tolerant of periods of cold
schemia and if you have any correlation at all in terms of the
eriod of ischemia and the outcomes related to older donors,
pecifically because their endothelial function may be somewhat
ifferent as to the donor’s age, and they may be more sensitive to
hose periods of ischemia.
Dr De Perrot. There are data from the International Society for
eart and Lung Transplantation that I’m sure you are aware of:
hey observed that the age of the donor and the ischemic time had
negative cumulative impact on outcome. But all these data were
ublished several years ago, and I think the quality of the lung
reservation has improved since then. The use of Perfadex and
ther improvements in the preservation technique have probably
elped to reduce the risk of prolonged ischemic times. In this series
f transplants, most of the ischemic times were somewhere be-
ween 6 and 8 hours. There were 4 patients who received older
ungs with an ischemic time longer than 8 hours, and they have
een doing well. I think the ischemic time doesn’t have so much
f an impact. I think it’s really more donor and recipient param-
ters that will affect the outcome.
Dr S. Yang (Baltimore, Maryland). If I could go back to the
rst article. In your data is there any way to answer some of these
ther questions about the older donor for the older patients? Were
ou able to see any trends?
Dr Nwakanma. We did not pay attention to that. It can be
one.
Dr Yang. It can be done.
Dr Nwakanma. Yes.
Dr Yang. That’s for next year’s talk.
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